This session will focus on the heterogeneity of mantle cell lymphoma (MCL). The clinical course shows a wide variation from an indolent subtype with CLL-like features to the highly aggressive blastoid variant with high cell proliferation.
Dr. Eva Hoster will review the currently evaluable biological risk scores with a special focus on minimal residual disease (MRD). MRD has been shown to be one of the most powerful predictive parameters in MCL. This lecture will focus on the underlying biology, technical caveats and therapeutic consequences, both in clinical trials and daily routine.
Dr. Simon Rule will give an overview of the currently established standards of frontline therapy, including bendamustine and cytarabine-containing regimens as well as autologous stem cell transplantation, but also elute to the role of targeted approaches (BTK inhibitors, IMIDs) currently tested in clinical trials.
Dr. Pierre-Louis Soubeyran will focus on the optimal treatment in “real” elderly patients. Although median age is around 65 years, only few data are available on more senior patients above 80 years with comorbidities. In particular, he will address the balance of expected toxicities and different aims of care.